LENZ Therapeutics, Inc./$LENZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Ticker
$LENZ
Sector
Primary listing
Employees
152
Headquarters
Website
LENZ Metrics
BasicAdvanced
$291m
-
-$2.85
1.76
-
Price and volume
Market cap
$291m
Beta
1.76
52-week high
$50.40
52-week low
$8.25
Average daily volume
1.1m
Financial strength
Current ratio
14.226
Quick ratio
13.913
Long term debt to equity
0.123
Total debt to equity
0.287
Profitability
EBITDA (TTM)
-90.851
Gross margin (TTM)
97.81%
Net profit margin (TTM)
-430.25%
Operating margin (TTM)
-477.46%
Effective tax rate (TTM)
-0.62%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-21.86%
Return on equity (TTM)
-33.63%
Valuation
Price to revenue (TTM)
14.023
Price to book
1.02
Price to tangible book (TTM)
1.02
Price to free cash flow (TTM)
-3.824
Free cash flow yield (TTM)
-26.15%
Free cash flow per share (TTM)
-2.429
Growth
Earnings per share change (TTM)
21.88%
3-year revenue growth (CAGR)
8.37%
3-year earnings per share growth (CAGR)
35.59%
LENZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LENZ Therapeutics, Inc. stock?
LENZ Therapeutics, Inc. (LENZ) has a market cap of $291M as of May 01, 2026.
What is the P/E ratio for LENZ Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) stock is 0 as of May 01, 2026.
Does LENZ Therapeutics, Inc. stock pay dividends?
No, LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next LENZ Therapeutics, Inc. dividend payment date?
LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders.
What is the beta indicator for LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. (LENZ) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.